Alpha-blockers and 5α-reductase inhibitors are applied as isolated or combined in the medical treatments of lower urinary tract symptoms related Benign Prostate Hyperplasia (BPH). We aimed to review recent improvement and treatment options in benign BPH in this review. This classical paradigm seems to be changed due to antimuscarinics, 5-phosphodiesterase inhibitors and β3- adrenoreceptor agonists. While silodosin medication provides effective reduction including nocturia at low urinary tract symptoms related BPH same time the cardiovascular side effects are rarely occurred. Antimuscarinics used isolated or in combined with α-blockers improved the storage symptoms without any poorly effect for the function of micturation. 5-phosphodiesterase inhibitors which are used solely improve BPH/low urinary tract symptoms. Combination of 5-phosphodiesterase inhibitors and α-blockers provides better symptomatic control than α-blockers alone. The standard medical treatment for BPH/low urinary tract symptoms is still based on α-blockers, 5α-reductase inhibitors or its combination. In the future, it is expected that BPH/low urinary tract symptoms treatment will become individualized, according to the type of symptoms, presence of sexual dysfunction and risk of benign prostate hyperplasia progression.

Keywords: Benign prostate hyperplasia, combined medical treatment, low urinary tract symptoms